Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage

Retrovirology

Volumn 6, Issue , 2009, Pages

  Kilareski, Evelyn M ^a   Shah, Sonia ^a   Nonnemacher, Michael R ^a   Wigdahl, Brian ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUCINE ZIPPER PROTEIN; MESSENGER RNA; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SP; VPR PROTEIN;

CELL LINEAGE; DNA BINDING; DNA METHYLATION; ENHANCER REGION; GENE DELETION; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENTIVIRINAE; LONG TERMINAL REPEAT; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOGENESIS; PROMOTER REGION; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRUS REPLICATION; GENETIC TRANSCRIPTION; HOST PATHOGEN INTERACTION; METABOLISM; PATHOGENICITY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY; VIRULENCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MACROPHAGES; MONOCYTES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; VIRULENCE; VIRUS REPLICATION;

EID: 74549196267     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-118     Document Type: Review

References (333)

1. HIV/AIDS UJUNPo AIDS Epidemic Update. 2007, HIV/AIDS UJUNPo.
2. Fusuma EE, Caruso SC, Lopez DF, Costa LJ, Janini LM, De Mendonca JS, Kallas EG, Diaz RS. Duplication of peri-kappaB and NF-kappab sites of the first human immunodeficiency virus type 2 (HIV-2) transmission in Brazil. AIDS Res Hum Retroviruses 2005, 21:965-970. 10.1089/aid.2005.21.965, 16386115.
3. Hightower M, Kallas EG. Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review. Braz J Infect Dis 2003, 7:7-15. 10.1590/S1413-86702003000100002, 12807687.
4. Grant AD, De Cock KM. ABC of AIDS. HIV infection and AIDS in the developing world. Bmj 2001, 322:1475-1478. 10.1136/bmj.322.7300.1475, 1120527, 11408309.
5. Markovitz DM. Infection with the human immunodeficiency virus type 2. Ann Intern Med 1993, 118:211-218.
6. Krebs FC, Ross H, McAllister J, Wigdahl B. HIV-1-associated central nervous system dysfunction. Adv Pharmacol 2000, 49:315-385. full_text, 11013768.
7. Wigdahl B, Guyton RA, Sarin PS. Human immunodeficiency virus infection of the developing human nervous system. Virology 1987, 159:440-445. 10.1016/0042-6822(87)90483-1, 3650007.
8. Wigdahl B, Kunsch C. Role of HIV in human nervous system dysfunction. AIDS Res Hum Retroviruses 1989, 5:369-374. 10.1089/aid.1989.5.369, 2669896.
9. Wigdahl B, Kunsch C. Human immunodeficiency virus infection and neurologic dysfunction. Prog Med Virol 1990, 37:1-46.
10. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986, 233:215-219. 10.1126/science.3014648, 3014648.
11. Gendelman HE, Orenstein JM, Baca LM, Weiser B, Burger H, Kalter DC, Meltzer MS. The macrophage in the persistence and pathogenesis of HIV infection. Aids 1989, 3:475-495.
12. Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 2009, 6:51. 10.1186/1742-4690-6-51, 2697150, 19486514.
13. Boggiano C, Littman DR. HIV's vagina travelogue. Immunity 2007, 26:145-147. 10.1016/j.immuni.2007.02.001, 17307703.
14. Milush JM, Kosub D, Marthas M, Schmidt K, Scott F, Wozniakowski A, Brown C, Westmoreland S, Sodora DL. Rapid dissemination of SIV following oral inoculation. AIDS 2004, 18:2371-2380.
15. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986, 83:7089-7093. 10.1073/pnas.83.18.7089, 386658, 3018755.
16. Ivey NS, MacLean AG, Lackner AA. Acquired immunodeficiency syndrome and the blood-brain barrier. J Neurovirol 2009, 15:111-122. 10.1080/13550280902769764, 19306229.
17. Chayt KJ, Harper ME, Marselle LM, Lewin EB, Rose RM, Oleske JM, Epstein LG, Wong-Staal F, Gallo RC. Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvement. Jama 1986, 256:2356-2359. 10.1001/jama.256.17.2356, 3639952.
18. Armstrong JA, Horne R. Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy. Lancet 1984, 2:370-372. 10.1016/S0140-6736(84)90540-3, 6147453.
19. Busch M, Beckstead J, Gantz D, Vyas G. Detection of human immunodeficiency virus infection of myeloid precursors in bone marrow samples from AIDS patients. Blood 1986, 68(Suppl 1):122a.
20. McElrath MJ, Pruett JE, Cohn ZA. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc Natl Acad Sci USA 1989, 86:675-679. 10.1073/pnas.86.2.675, 286536, 2492110.
21. Atta MG, Lucas GM, Fine DM. HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management. Expert Rev Anti Infect Ther 2008, 6:365-371. 10.1586/14787210.6.3.365, 18588500.
22. Brown A, Zhang H, Lopez P, Pardo CA, Gartner S. In vitro modeling of the HIV-macrophage reservoir. J Leukoc Biol 2006, 80:1127-1135. 10.1189/jlb.0206126, 16923921.
23. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986, 233:1089-1093. 10.1126/science.3016903, 3016903.
24. Schrier RD, McCutchan JA, Venable JC, Nelson JA, Wiley CA. T-cell-induced expression of human immunodeficiency virus in macrophages. J Virol 1990, 64:3280-3288. 249555, 2112615.
25. Garcia-Blanco MA, Cullen BR. Molecular basis of latency in pathogenic human viruses. Science 1991, 254:815-820. 10.1126/science.1658933, 1658933.
26. Rich EA, Chen IS, Zack JA, Leonard ML, O'Brien WA. Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). J Clin Invest 1992, 89:176-183. 10.1172/JCI115559, 442834, 1370293.
27. Mikovits JA, Raziuddin, Gonda M, Ruta M, Lohrey NC, Kung HF, Ruscetti FW. Negative regulation of human immune deficiency virus replication in monocytes. Distinctions between restricted and latent expression in THP-1 cells. J Exp Med 1990, 171:1705-1720. 10.1084/jem.171.5.1705, 2187891, 2332735.
28. Mann DL, Gartner S, Le Sane F, Buchow H, Popovic M. HIV-1 transmission and function of virus-infected monocytes/macrophages. J Immunol 1990, 144:2152-2158.
29. Sabatier JM, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A, Hue B, Bahraoui E. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol 1991, 65:961-967. 239839, 1898974.
30. Giulian D, Wendt E, Vaca K, Noonan CA. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes. Proc Natl Acad Sci USA 1993, 90:2769-2773. 10.1073/pnas.90.7.2769, 46177, 8464887.
31. Wu P, Price P, Du B, Hatch WC, Terwilliger EF. Direct cytotoxicity of HIV-1 envelope protein gp120 on human NT neurons. Neuroreport 1996, 7:1045-1049.
32. Esser R, von Briesen H, Brugger M, Ceska M, Glienke W, Muller S, Rehm A, Rubsamen-Waigmann H, Andreesen R. Secretory repertoire of HIV-infected human monocytes/macrophages. Pathobiology 1991, 59:219-222. 10.1159/000163649, 1909144.
33. Cox RA, Anders GT, Cappelli PJ, Johnson JE, Blanton HM, Seaworth BJ, Treasure RL. Production of tumor necrosis factor-alpha and interleukin-1 by alveolar macrophages from HIV-1-infected persons. AIDS Res Hum Retroviruses 1990, 6:431-441. 10.1089/aid.1990.6.431, 2340204.
34. Nakajima K, Martinez-Maza O, Hirano T, Breen EC, Nishanian PG, Salazar-Gonzalez JF, Fahey JL, Kishimoto T. Induction of IL-6 (B cell stimulatory factor-2/IFN-beta 2) production by HIV. J Immunol 1989, 142:531-536.
35. Roy S, Fitz-Gibbon L, Poulin L, Wainberg MA. Infection of human monocytes/macrophages by HIV-1: effect on secretion of IL-1 activity. Immunology 1988, 64:233-239. 1384948, 3260578.
36. Alexaki A, Quiterio SJ, Liu Y, Irish B, Kilareski E, Nonnemacher MR, Wigdahl B. PMA-induced differentiation of a bone marrow progenitor cell line activates HIV-1 LTR-driven transcription. DNA Cell Biol 2007, 26:387-394. 10.1089/dna.2006.0542, 17570762.
37. Fields BN, Knipe DM, Howley PM. Fields' virology 2007, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 5.
38. Krebs FC, Mehrens D, Pomeroy S, Goodenow MM, Wigdahl B. Human immunodeficiency virus type 1 long terminal repeat quasispecies differ in basal transcription and nuclear factor recruitment in human glial cells and lymphocytes. J Biomed Sci 1998, 5:31-44. 10.1007/BF02253354, 9570512.
39. McAllister JJ, Phillips D, Millhouse S, Conner J, Hogan T, Ross HL, Wigdahl B. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication. Virology 2000, 274:262-277. 10.1006/viro.2000.0476, 10964770.
40. Millhouse S, Krebs FC, Yao J, McAllister JJ, Conner J, Ross H, Wigdahl B. Sp1 and related factors fail to interact with the NF-kappaB-proximal G/C box in the LTR of a replication competent, brain-derived strain of HIV-1 (YU-2). J Neurovirol 1998, 4:312-323. 10.3109/13550289809114532, 9639074.
41. Nonnemacher MR, Irish BP, Liu Y, Mauger D, Wigdahl B. Specific sequence configurations of HIV-1 LTR G/C box array result in altered recruitment of Sp isoforms and correlate with disease progression. J Neuroimmunol 2004, 157:39-47. 10.1016/j.jneuroim.2004.08.021, 15579278.
42. Ross HL, Gartner S, McArthur JC, Corboy JR, McAllister JJ, Millhouse S, Wigdahl B. HIV-1 LTR C/EBP binding site sequence configurations preferentially encountered in brain lead to enhanced C/EBP factor binding and increased LTR-specific activity. J Neurovirol 2001, 7:235-249. 10.1080/13550280152403281, 11517398.
43. Hogan TH, Stauff DL, Krebs FC, Gartner S, Quiterio SJ, Wigdahl B. Structural and functional evolution of human immunodeficiency virus type 1 long terminal repeat CCAAT/enhancer binding protein sites and their use as molecular markers for central nervous system disease progression. J Neurovirol 2003, 9:55-68.
44. Burdo TH, Gartner S, Mauger D, Wigdahl B. Region-specific distribution of human immunodeficiency virus type 1 long terminal repeats containing specific configurations of CCAAT/enhancer-binding protein site II in brains derived from demented and nondemented patients. J Neurovirol 2004, 10(Suppl 1):7-14.
45. Burdo TH, Nonnemacher M, Irish BP, Choi CH, Krebs FC, Gartner S, Wigdahl B. High-affinity interaction between HIV-1 Vpr and specific sequences that span the C/EBP and adjacent NF-kappaB sites within the HIV-1 LTR correlate with HIV-1-associated dementia. DNA Cell Biol 2004, 23:261-269. 10.1089/104454904773819842, 15142383.
46. Hogan TH, Nonnemacher MR, Krebs FC, Henderson A, Wigdahl B. HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and adjacent regions is sequence-specific. Biomed Pharmacother 2003, 57:41-48. 10.1016/S0753-3322(02)00333-5, 12642036.
47. Yu W, Wang Y, Shaw CA, Qin XF, Rice AP. Induction of the HIV-1 Tat co-factor cyclin T1 during monocyte differentiation is required for the regulated expression of a large portion of cellular mRNAs. Retrovirology 2006, 3:32. 10.1186/1742-4690-3-32, 1557533, 16764723.
48. Bernstein MS, Tong-Starksen SE, Locksley RM. Activation of human monocyte--derived macrophages with lipopolysaccharide decreases human immunodeficiency virus replication in vitro at the level of gene expression. J Clin Invest 1991, 88:540-545. 10.1172/JCI115337, 295381, 1907615.
49. Molina JM, Scadden DT, Byrn R, Dinarello CA, Groopman JE. Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest 1989, 84:733-737. 10.1172/JCI114230, 329713, 2474573.
50. Pomerantz RJ, Feinberg MB, Trono D, Baltimore D. Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression. J Exp Med 1990, 172:253-261. 10.1084/jem.172.1.253, 2188186, 2193097.
51. Poli G, Kinter A, Justement JS, Kehrl JH, Bressler P, Stanley S, Fauci AS. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990, 87:782-785. 10.1073/pnas.87.2.782, 53350, 2300561.
52. Koyanagi Y, O'Brien WA, Zhao JQ, Golde DW, Gasson JC, Chen IS. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988, 241:1673-1675. 10.1126/science.3047875, 3047875.
53. Folks TM, Kessler SW, Orenstein JM, Justement JS, Jaffe ES, Fauci AS. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988, 242:919-922. 10.1126/science.2460922, 2460922.
54. Dong C, Kwas C, Wu L. Transcriptional restriction of human immunodeficiency virus type 1 gene expression in undifferentiated primary monocytes. J Virol 2009, 83:3518-3527. 10.1128/JVI.02665-08, 2663290, 19211771.
55. Sundaravaradan V, Saxena SK, Ramakrishnan R, Yedavalli VR, Harris DT, Ahmad N. Differential HIV-1 replication in neonatal and adult blood mononuclear cells is influenced at the level of HIV-1 gene expression. Proc Natl Acad Sci USA 2006, 103:11701-11706. 10.1073/pnas.0602185103, 1544233, 16868088.
56. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997, 276:1857-1861. 10.1126/science.276.5320.1857, 9188531.
57. Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischofberger N, Hirsch V, Martin MA. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci USA 2001, 98:658-663. 10.1073/pnas.021551798, 14644, 11136236.
58. Jones KA, Kadonaga JT, Luciw PA, Tjian R. Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science 1986, 232:755-759. 10.1126/science.3008338, 3008338.
59. Canonne-Hergaux F, Aunis D, Schaeffer E. Interactions of the transcription factor AP-1 with the long terminal repeat of different human immunodeficiency virus type 1 strains in Jurkat, glial, and neuronal cells. J Virol 1995, 69:6634-6642. 189572, 7474072.
60. Van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E. Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J Virol 1997, 71:6113-6127. 191872, 9223506.
61. Peeters A, Lambert PF, Deacon NJ. A fourth Sp1 site in the human immunodeficiency virus type 1 long terminal repeat is essential for negative-sense transcription. J Virol 1996, 70:6665-6672. 190708, 8794302.
62. Hagen G, Muller S, Beato M, Suske G. Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes. Nucleic Acids Res 1992, 20:5519-5525. 10.1093/nar/20.21.5519, 334381, 1454515.
63. Dynan WS, Tjian R. Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II. Cell 1983, 32:669-680. 10.1016/0092-8674(83)90053-3, 6187469.
64. Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 1987, 51:1079-1090. 10.1016/0092-8674(87)90594-0, 3319186.
65. Kingsley C, Winoto A. Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol Cell Biol 1992, 12:4251-4261. 360348, 1341900.
66. Majello B, De Luca P, Hagen G, Suske G, Lania L. Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1. Nucleic Acids Res 1994, 22:4914-4921. 10.1093/nar/22.23.4914, 523756, 7800480.
67. Hagen G, Muller S, Beato M, Suske G. Sp1-mediated transcriptional activation is repressed by Sp3. Embo J 1994, 13:3843-3851. 395297, 8070411.
68. Udvadia AJ, Templeton DJ, Horowitz JM. Functional interactions between the retinoblastoma (Rb) protein and Sp-family members: superactivation by Rb requires amino acids necessary for growth suppression. Proc Natl Acad Sci USA 1995, 92:3953-3957. 10.1073/pnas.92.9.3953, 42080, 7732011.
69. Kennett SB, Udvadia AJ, Horowitz JM. Sp3 encodes multiple proteins that differ in their capacity to stimulate or repress transcription. Nucleic Acids Res 1997, 25:3110-3117. 10.1093/nar/25.15.3110, 146854, 9224612.
70. Supp DM, Witte DP, Branford WW, Smith EP, Potter SS. Sp4, a member of the Sp1-family of zinc finger transcription factors, is required for normal murine growth, viability, and male fertility. Dev Biol 1996, 176:284-299. 10.1006/dbio.1996.0134, 8660867.
71. Hagen G, Dennig J, Preiss A, Beato M, Suske G. Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3. J Biol Chem 1995, 270:24989-24994. 10.1074/jbc.270.42.24989, 7559627.
72. Gill G, Pascal E, Tseng ZH, Tjian R. A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation. Proc Natl Acad Sci USA 1994, 91:192-196. 10.1073/pnas.91.1.192, 42912, 8278363.
73. Emili A, Greenblatt J, Ingles CJ. Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. Mol Cell Biol 1994, 14:1582-1593. 358517, 8114696.
74. Chiang CM, Roeder RG. Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators. Science 1995, 267:531-536. 10.1126/science.7824954, 7824954.
75. Huang LM, Jeang KT. Increased spacing between Sp1 and TATAA renders human immunodeficiency virus type 1 replication defective: implication for Tat function. J Virol 1993, 67:6937-6944. 238151, 8230415.
76. Yedavalli VS, Benkirane M, Jeang KT. Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem 2003, 278:6404-6410. 10.1074/jbc.M209162200, 12458222.
77. Widlak P, Gaynor RB, Garrard WT. In vitro chromatin assembly of the HIV-1 promoter. ATP-dependent polar repositioning of nucleosomes by Sp1 and NFkappaB. J Biol Chem 1997, 272:17654-17661. 10.1074/jbc.272.28.17654, 9211915.
78. Pazin MJ, Sheridan PL, Cannon K, Cao Z, Keck JG, Kadonaga JT, Jones KA. NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev 1996, 10:37-49. 10.1101/gad.10.1.37, 8557193.
79. Won J, Yim J, Kim TK. Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J Biol Chem 2002, 277:38230-38238. 10.1074/jbc.M206064200, 12151407.
80. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, Seiser C. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 1999, 19:5504-5511. 84392, 10409740.
81. Sun JM, Chen HY, Moniwa M, Litchfield DW, Seto E, Davie JR. The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2. J Biol Chem 2002, 277:35783-35786. 10.1074/jbc.C200378200, 12176973.
82. Li Y, Mak G, Franza BR. In vitro study of functional involvement of Sp1, NF-kappa B/Rel, and AP1 in phorbol 12-myristate 13-acetate-mediated HIV-1 long terminal repeat activation. J Biol Chem 1994, 269:30616-30619.
83. Moses AV, Ibanez C, Gaynor R, Ghazal P, Nelson JA. Differential role of long terminal repeat control elements for the regulation of basal and Tat-mediated transcription of the human immunodeficiency virus in stimulated and unstimulated primary human macrophages. J Virol 1994, 68:298-307. 236289, 8254741.
84. Du Z, Ilyinskii PO, Sasseville VG, Newstein M, Lackner AA, Desrosiers RC. Requirements for lymphocyte activation by unusual strains of simian immunodeficiency virus. J Virol 1996, 70:4157-4161. 190308, 8648760.
85. Ilyinskii PO, Desrosiers RC. Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-kappaB and Sp1 binding elements. J Virol 1996, 70:3118-3126. 190174, 8627791.
86. Ilyinskii PO, Simon MA, Czajak SC, Lackner AA, Desrosiers RC. Induction of AIDS by simian immunodeficiency virus lacking NF-kappaB and SP1 binding elements. J Virol 1997, 71:1880-1887. 191258, 9032318.
87. Resendes KK, Rosmarin AG. Sp1 control of gene expression in myeloid cells. Crit Rev Eukaryot Gene Expr 2004, 14:171-181. 10.1615/CritRevEukaryotGeneExpr.v14.i3.20, 15248814.
88. Chu S, Ferro TJ. Sp1: regulation of gene expression by phosphorylation. Gene 2005, 348:1-11. 10.1016/j.gene.2005.01.013, 15777659.
89. Jackson S, Gottlieb T, Hartley K. Phosphorylation of transcription factor Sp1 by the DNA-dependent protein kinase. Adv Second Messenger Phosphoprotein Res 1993, 28:279-286.
90. Jackson SP, MacDonald JJ, Lees-Miller S, Tjian R. GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell 1990, 63:155-165. 10.1016/0092-8674(90)90296-Q, 2170018.
91. Vlach J, Garcia A, Jacque JM, Rodriguez MS, Michelson S, Virelizier JL. Induction of Sp1 phosphorylation and NF-kappa B-independent HIV promoter domain activity in T lymphocytes stimulated by okadaic acid. Virology 1995, 208:753-761. 10.1006/viro.1995.1207, 7747447.
92. Chun RF, Semmes OJ, Neuveut C, Jeang KT. Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J Virol 1998, 72:2615-2629. 109697, 9525578.
93. Jochmann R, Thurau M, Jung S, Hofmann C, Naschberger E, Kremmer E, Harrer T, Miller M, Schaft N, Sturzl M. O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter. J Virol 2009, 83:3704-3718. 10.1128/JVI.01384-08, 2663287, 19193796.
94. Mingyan Y, Xinyong L, De Clercq E. NF-kappaB: the inducible factors of HIV-1 transcription and their inhibitors. Mini Rev Med Chem 2009, 9:60-69. 10.2174/138955709787001677, 19149660.
95. Roulston A, Lin R, Beauparlant P, Wainberg MA, Hiscott J. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev 1995, 59:481-505. 239370, 7565415.
96. Phares W, Franza BR, Herr W. The kappa B enhancer motifs in human immunodeficiency virus type 1 and simian virus 40 recognize different binding activities in human Jurkat and H9 T cells: evidence for NF-kappa B-independent activation of the kappa B motif. J Virol 1992, 66:7490-7498. 240457, 1331533.
97. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987, 326:711-713. 10.1038/326711a0, 3031512.
98. Asin S, Bren GD, Carmona EM, Solan NJ, Paya CV. NF-kappaB cis-acting motifs of the human immunodeficiency virus (HIV) long terminal repeat regulate HIV transcription in human macrophages. J Virol 2001, 75:11408-11416. 10.1128/JVI.75.23.11408-11416.2001, 114727, 11689622.
99. Asin S, Taylor JA, Trushin S, Bren G, Paya CV. Ikappakappa mediates NF-kappaB activation in human immunodeficiency virus-infected cells. J Virol 1999, 73:3893-3903. 104167, 10196284.
100. Neumann M, Fries H, Scheicher C, Keikavoussi P, Kolb-Maurer A, Brocker E, Serfling E, Kampgen E. Differential expression of Rel/NF-kappaB and octamer factors is a hallmark of the generation and maturation of dendritic cells. Blood 2000, 95:277-285.
101. Baeuerle P, Baltimore D. Activation of DNA-Binding Activity in an Apparently Cytoplasmic Precursor of the NF-KB Transcription Factor. Cell 1988, 53:211-217. 10.1016/0092-8674(88)90382-0, 3129195.
102. Beg AA, Finco TS, Nantermet PV, Baldwin AS. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol 1993, 13:3301-3310. 359784, 8497253.
103. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 2001, 8:327-337. 10.1016/S1097-2765(01)00314-8, 11545735.
104. Coiras M, Lopez-Huertas MR, Rullas J, Mittelbrunn M, Alcami J. Basal shuttle of NF-kappaB/I kappaB alpha in resting T lymphocytes regulates HIV-1 LTR dependent expression. Retrovirology 2007, 4:56. 10.1186/1742-4690-4-56, 1988826, 17686171.
105. Ashburner BP, Westerheide SD, Baldwin AS. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001, 21:7065-7077. 10.1128/MCB.21.20.7065-7077.2001, 99882, 11564889.
106. Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ. Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature 1989, 339:70-73. 10.1038/339070a0, 2654643.
107. Roulston A, Beauparlant P, Rice N, Hiscott J. Chronic human immunodeficiency virus type 1 infection stimulates distinct NF-kappa B/rel DNA binding activities in myelomonoblastic cells. J Virol 1993, 67:5235-5246. 237921, 8394446.
108. Perkins ND, Agranoff AB, Pascal E, Nabel GJ. An interaction between the DNA-binding domains of RelA(p65) and Sp1 mediates human immunodeficiency virus gene activation. Mol Cell Biol 1994, 14:6570-6583. 359187, 7935378.
109. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. Embo J 1993, 12:3551-3558. 413631, 8253080.
110. Cron RQ, Bartz SR, Clausell A, Bort SJ, Klebanoff SJ, Lewis DB. NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells. Clin Immunol 2000, 94:179-191. 10.1006/clim.1999.4831, 10692237.
111. Kawakami K, Scheidereit C, Roeder RG. Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. Proc Natl Acad Sci USA 1988, 85:4700-4704. 10.1073/pnas.85.13.4700, 280503, 3133660.
112. Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 1997, 6:235-244. 10.1016/S1074-7613(00)80326-X, 9075924.
113. Berg RS, Aggerholm A, Bertelsen LS, Ostergaard L, Paludan SR. Role of mitogen-activated protein kinases, nuclear factor-kappaB, and interferon regulatory factor 3 in Toll-like receptor 4-mediated activation of HIV long terminal repeat. APMIS 2009, 117:124-132.
114. Mallardo M, Dragonetti E, Baldassarre F, Ambrosino C, Scala G, Quinto I. An NF-kappaB site in the 5'-untranslated leader region of the human immunodeficiency virus type 1 enhances the viral expression in response to NF-kappaB-activating stimuli. J Biol Chem 1996, 271:20820-20827. 10.1074/jbc.271.34.20820, 8702837.
115. Montano MA, Kripke K, Norina CD, Achacoso P, Herzenberg LA, Roy AL, Nolan GP. NF-kappa B homodimer binding within the HIV-1 initiator region and interactions with TFII-I. Proc Natl Acad Sci USA 1996, 93:12376-12381. 10.1073/pnas.93.22.12376, 37999, 8901589.
116. Parrott C, Seidner T, Duh E, Leonard J, Theodore TS, Buckler-White A, Martin MA, Rabson AB. Variable role of the long terminal repeat Sp1-binding sites in human immunodeficiency virus replication in T lymphocytes. J Virol 1991, 65:1414-1419. 239920, 1995951.
117. Ross EK, Buckler-White AJ, Rabson AB, Englund G, Martin MA. Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J Virol 1991, 65:4350-4358. 248874, 2072454.
118. Leonard J, Parrott C, Buckler-White AJ, Turner W, Ross EK, Martin MA, Rabson AB. The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol 1989, 63:4919-4924. 251138, 2795721.
119. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 2002, 109(Suppl):S67-79. 10.1016/S0092-8674(02)00699-2, 11983154.
120. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003, 17:2205-2232. 10.1101/gad.1102703, 12975316.
121. Lopez-Rodriguez C, Aramburu J, Rakeman AS, Rao A. NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc Natl Acad Sci USA 1999, 96:7214-7219. 10.1073/pnas.96.13.7214, 22056, 10377394.
122. Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR. Identification of a putative regulator of early T cell activation genes. Science 1988, 241:202-205. 10.1126/science.3260404, 3260404.
123. Serfling E, Berberich-Siebelt F, Avots A, Chuvpilo S, Klein-Hessling S, Jha MK, Kondo E, Pagel P, Schulze-Luehrmann J, Palmetshofer A. NFAT and NF-kappaB factors-the distant relatives. Int J Biochem Cell Biol 2004, 36:1166-1170. 10.1016/j.biocel.2003.07.002, 15109564.
124. Fortin JF, Barbeau B, Robichaud GA, Pare ME, Lemieux AM, Tremblay MJ. Regulation of nuclear factor of activated T cells by phosphotyrosyl-specific phosphatase activity: a positive effect on HIV-1 long terminal repeat-driven transcription and a possible implication of SHP-1. Blood 2001, 97:2390-2400. 10.1182/blood.V97.8.2390, 11290602.
125. Crabtree GR. Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell 1999, 96:611-614. 10.1016/S0092-8674(00)80571-1, 10089876.
126. Stankunas K, Graef IA, Neilson JR, Park SH, Crabtree GR. Signaling through calcium, calcineurin, and NF-AT in lymphocyte activation and development. Cold Spring Harb Symp Quant Biol 1999, 64:505-516. 10.1101/sqb.1999.64.505, 11232327.
127. Giffin MJ, Stroud JC, Bates DL, von Koenig KD, Hardin J, Chen L. Structure of NFAT1 bound as a dimer to the HIV-1 LTR kappa B element. Nat Struct Biol 2003, 10:800-806. 10.1038/nsb981, 12949493.
128. Bates DL, Barthel KK, Wu Y, Kalhor R, Stroud JC, Giffin MJ, Chen L. Crystal Structure of NFAT Bound to the HIV-1 LTR Tandem kappaB Enhancer Element. Structure 2008, 16:684-694. 10.1016/j.str.2008.01.020, 2697820, 18462673.
129. de Lumley M, Hart DJ, Cooper MA, Symeonides S, Blackburn JM. A biophysical characterisation of factors controlling dimerisation and selectivity in the NF-kappaB and NFAT families. J Mol Biol 2004, 339:1059-1075. 10.1016/j.jmb.2004.03.083, 15178248.
130. Ranjbar S, Tsytsykova AV, Lee SK, Rajsbaum R, Falvo JV, Lieberman J, Shankar P, Goldfeld AE. NFAT5 regulates HIV-1 in primary monocytes via a highly conserved long terminal repeat site. PLoS Pathog 2006, 2:e130. 10.1371/journal.ppat.0020130, 1698943,1698943, 17173480.
131. Markovitz DM, Hannibal MC, Smith MJ, Cossman R, Nabel GJ. Activation of the human immunodeficiency virus type 1 enhancer is not dependent on NFAT-1. J Virol 1992, 66:3961-3965. 241190, 1533884.
132. Lu YC, Touzjian N, Stenzel M, Dorfman T, Sodroski JG, Haseltine WA. Identification of cis-acting repressive sequences within the negative regulatory element of human immunodeficiency virus type 1. J Virol 1990, 64:5226-5229. 248024, 2398545.
133. Kinoshita S, Chen BK, Kaneshima H, Nolan GP. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 1998, 95:595-604. 10.1016/S0092-8674(00)81630-X, 9845362.
134. Manley K, O'Hara BA, Gee GV, Simkevich CP, Sedivy JM, Atwood WJ. NFAT4 is required for JC virus infection of glial cells. J Virol 2006, 80:12079-12085. 10.1128/JVI.01456-06, 1676291, 17035332.
135. Sica A, Dorman L, Viggiano V, Cippitelli M, Ghosh P, Rice N, Young HA. Interaction of NF-kappaB and NFAT with the interferon-gamma promoter. J Biol Chem 1997, 272:30412-30420. 10.1074/jbc.272.48.30412, 9374532.
136. Romanchikova N, Ivanova V, Scheller C, Jankevics E, Jassoy C, Serfling E. NFAT transcription factors control HIV-1 expression through a binding site downstream of TAR region. Immunobiology 2003, 208:361-365. 10.1078/0171-2985-00283, 14748509.
137. Macian F, Rao A. Reciprocal modulatory interaction between human immunodeficiency virus type 1 Tat and transcription factor NFAT1. Mol Cell Biol 1999, 19:3645-3653. 84169, 10207088.
138. Pessler F, Cron RQ. Reciprocal regulation of the nuclear factor of activated T cells and HIV-1. Genes Immun 2004, 5:158-167. 10.1038/sj.gene.6364047, 14762397.
139. Cron RQ. HIV-1, NFAT, and cyclosporin: immunosuppression for the immunosuppressed?. DNA Cell Biol 2001, 20:761-767. 10.1089/104454901753438570, 11879569.
140. Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res 2000, 28:663-668. 10.1093/nar/28.3.663, 102541, 10637316.
141. Ilyinskii PO, Daniel MD, Simon MA, Lackner AA, Desrosiers RC. The role
142. Kirchhoff F, Kestler HW, Desrosiers RC. Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene. J Virol 1994, 68:2031-2037. 236672, 8107267.
143. Pohlmann S, Floss S, Ilyinskii PO, Stamminger T, Kirchhoff F. Sequences just upstream of the simian immunodeficiency virus core enhancer allow efficient replication in the absence of NF-kappaB and Sp1 binding elements. J Virol 1998, 72:5589-5598. 110216, 9621017.
144. Rosen CA, Sodroski JG, Haseltine WA. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell 1985, 41:813-823. 10.1016/S0092-8674(85)80062-3, 2988790.
145. Nonnemacher MR, Hogan TH, Quiterio S, Wigdahl B, Henderson A, Krebs FC. Identification of binding sites for members of the CCAAT/enhancer binding protein transcription factor family in the simian immunodeficiency virus long terminal repeat. Biomed Pharmacother 2003, 57:34-40. 10.1016/S0753-3322(02)00334-7, 12642035.
146. Ross HL, Nonnemacher MR, Hogan TH, Quiterio SJ, Henderson A, McAllister JJ, Krebs FC, Wigdahl B. Interaction between CCAAT/enhancer binding protein and cyclic AMP response element binding protein 1 regulates human immunodeficiency virus type 1 transcription in cells of the monocyte/macrophage lineage. J Virol 2001, 75:1842-1856. 10.1128/JVI.75.4.1842-1856.2001, 114094, 11160683.
147. Quiterio S, Grant C, Hogan TH, Krebs FC, Wigdahl B. C/EBP- and Tat-mediated activation of the HIV-1 LTR in CD34+ hematopoietic progenitor cells. Biomed Pharmacother 2003, 57:49-56. 10.1016/S0753-3322(02)00332-3, 12642037.
148. Deppmann CD, Alvania RS, Taparowsky EJ. Cross-species annotation of basic leucine zipper factor interactions: Insight into the evolution of closed interaction networks. Mol Biol Evol 2006, 23:1480-1492. 10.1093/molbev/msl022, 16731568.
149. Landschulz WH, Johnson PF, McKnight SL. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 1988, 240:1759-1764. 10.1126/science.3289117, 3289117.
150. Cai DH, Wang D, Keefer J, Yeamans C, Hensley K, Friedman AD. C/EBP alpha:AP-1 leucine zipper heterodimers bind novel DNA elements, activate the PU.1 promoter and direct monocyte lineage commitment more potently than C/EBP alpha homodimers or AP-1. Oncogene 2008, 27:2772-2779. 10.1038/sj.onc.1210940, 2696120, 18026136.
151. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA 1991, 88:3720-3724. 10.1073/pnas.88.9.3720, 51524, 1827203.
152. Gombart AF, Grewal J, Koeffler HP. ATF4 differentially regulates transcriptional activation of myeloid-specific genes by C/EBPepsilon and C/EBPalpha. J Leukoc Biol 2007, 81:1535-1547. 10.1189/jlb.0806516, 17347301.
153. Hsu W, Kerppola TK, Chen PL, Curran T, Chen-Kiang S. Fos and Jun repress transcription activation by NF-IL6 through association at the basic zipper region. Mol Cell Biol 1994, 14:268-276. 358376, 8264594.
154. Rangatia J, Vangala RK, Treiber N, Zhang P, Radomska H, Tenen DG, Hiddemann W, Behre G. Downregulation of c-Jun expression by transcription factor C/EBPalpha is critical for granulocytic lineage commitment. Mol Cell Biol 2002, 22:8681-8694. 10.1128/MCB.22.24.8681-8694.2002, 139872, 12446786.
155. Nolan GP. NF-AT-AP-1 and Rel-bZIP: hybrid vigor and binding under the influence. Cell 1994, 77:795-798. 10.1016/0092-8674(94)90126-0, 8004669.
156. Mondal D, Alam J, Prakash O. NF-kappa B site-mediated negative regulation of the HIV-1 promoter by CCAAT/enhancer binding proteins in brain-derived cells. J Mol Neurosci 1994, 5:241-258. 10.1007/BF02736725, 7577367.
157. Tesmer VM, Rajadhyaksha A, Babin J, Bina M. NF-IL6-mediated transcriptional activation of the long terminal repeat of the human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993, 90:7298-7302. 10.1073/pnas.90.15.7298, 47124, 8346247.
158. Henderson AJ, Zou X, Calame KL. C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. J Virol 1995, 69:5337-5344. 189374, 7636977.
159. Henderson AJ, Connor RI, Calame KL. C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines. Immunity 1996, 5:91-101. 10.1016/S1074-7613(00)80313-1, 8758898.
160. Yang Y, Pares-Matos EI, Tesmer VM, Dai C, Ashworth S, Huai J, Bina M. Organization of the promoter region of the human NF-IL6 gene. Biochim Biophys Acta 2002, 1577:102-108.
161. Tesmer VM, Bina M. Regulation of HIV-1 gene expression by NF-IL6. J Mol Biol 1996, 262:327-335. 10.1006/jmbi.1996.0516, 8844998.
162. Kinoshita SM, Taguchi S. NF-IL6 (C/EBPbeta) induces HIV-1 replication by inhibiting cytidine deaminase APOBEC3G. Proc Natl Acad Sci USA 2008, 105:15022-15027. 10.1073/pnas.0807269105, 2567486, 18809921.
163. Landschulz WH, Johnson PF, Adashi EY, Graves BJ, McKnight SL. Isolation of a recombinant copy of the gene encoding C/EBP. Genes Dev 1988, 2:786-800. 10.1101/gad.2.7.786, 2850264.
164. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, Nakajima T, Hirano T, Kishimoto T. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 1990, 9:1897-1906. 551896, 2112087.
165. Chang CJ, Chen TT, Lei HY, Chen DS, Lee SC. Molecular cloning of a transcription factor, AGP/EBP, that belongs to members of the C/EBP family. Mol Cell Biol 1990, 10:6642-6653. 362942, 1701020.
166. Antonson P, Stellan B, Yamanaka R, Xanthopoulos KG. A novel human CCAAT/enhancer binding protein gene, C/EBPepsilon, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor alpha/delta locus. Genomics 1996, 35:30-38. 10.1006/geno.1996.0319, 8661101.
167. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992, 6:439-453. 10.1101/gad.6.3.439, 1547942.
168. Cooper C, Henderson A, Artandi S, Avitahl N, Calame K. Ig/EBP (C/EBP gamma) is a transdominant negative inhibitor of C/EBP family transcriptional activators. Nucleic Acids Res 1995, 23:4371-4377. 10.1093/nar/23.21.4371, 307392, 7501458.
169. Poli V, Mancini FP, Cortese R. IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. Cell 1990, 63:643-653. 10.1016/0092-8674(90)90459-R, 2171780.
170. Descombes P, Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 1991, 67:569-579. 10.1016/0092-8674(91)90531-3, 1934061.
171. Eaton E, Hanlon M, Bundy L, Sealy L. Characterization of C/EBPbeta isoforms in normal versus neoplastic mammary epithelial cells. J Cell Physiol. 2001, 189(1):91-105.
172. Scott LM, Civin CI, Rorth P, Friedman AD. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 1992, 80:1725-1735.
173. Natsuka S, Akira S, Nishio Y, Hashimoto S, Sugita T, Isshiki H, Kishimoto T. Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin-6. Blood 1992, 79:460-466.
174. Tengku-Muhammad TS, Hughes TR, Ranki H, Cryer A, Ramji DP. Differential regulation of macrophage CCAAT-enhancer binding protein isoforms by lipopolysaccharide and cytokines. Cytokine 2000, 12:1430-1436. 10.1006/cyto.2000.0711, 10976009.
175. Williams SC, Baer M, Dillner AJ, Johnson PF. CRP2 (C/EBP beta) contains a bipartite regulatory domain that controls transcriptional activation, DNA binding and cell specificity. EMBO J 1995, 14:3170-3183. 394378, 7621830.
176. Kowenz-Leutz E, Twamley G, Ansieau S, Leutz A. Novel mechanism of C/EBP beta (NF-M) transcriptional control: activation through derepression. Genes Dev 1994, 8:2781-2791. 10.1101/gad.8.22.2781, 7958933.
177. Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T, Akira S. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci USA 1993, 90:2207-2211. 10.1073/pnas.90.6.2207, 46055, 8384717.
178. Chinery R, Brockman JA, Dransfield DT, Coffey RJ. Antioxidant-induced nuclear translocation of CCAAT/enhancer-binding protein beta. A critical role for protein kinase A-mediated phosphorylation of Ser299. J Biol Chem 1997, 272:30356-30361. 10.1074/jbc.272.48.30356, 9374525.
179. Mameli G, Deshmane SL, Ghafouri M, Cui J, Simbiri K, Khalili K, Mukerjee R, Dolei A, Amini S, Sawaya BE. C/EBPbeta regulates human immunodeficiency virus 1 gene expression through its association with cdk9. J Gen Virol 2007, 88:631-640. 10.1099/vir.0.82487-0, 17251582.
180. Kowenz-Leutz E, Leutz A. A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes. Mol Cell 1999, 4:735-743. 10.1016/S1097-2765(00)80384-6, 10619021.
181. Lee ES, Sarma D, Zhou H, Henderson AJ. CCAAT/enhancer binding proteins are not required for HIV-1 entry but regulate proviral transcription by recruiting coactivators to the long-terminal repeat in monocytic cells. Virology 2002, 299:20-31. 10.1006/viro.2002.1500, 12167337.
182. Wang H, Larris B, Peiris TH, Zhang L, Le Lay J, Gao Y, Greenbaum LE. C/EBPbeta activates E2F-regulated genes in vivo via recruitment of the coactivator CREB-binding protein/P300. J Biol Chem 2007, 282:24679-24688. 10.1074/jbc.M705066200, 17599912.
183. Mink S, Haenig B, Klempnauer KH. Interaction and functional collaboration of p300 and C/EBPbeta. Mol Cell Biol 1997, 17:6609-6617. 232514, 9343424.
184. Schwartz C, Beck K, Mink S, Schmolke M, Budde B, Wenning D, Klempnauer KH. Recruitment of p300 by C/EBPbeta triggers phosphorylation of p300 and modulates coactivator activity. EMBO J 2003, 22:882-892. 10.1093/emboj/cdg076, 145436, 12574124.
185. Schwartz C, Catez P, Rohr O, Lecestre D, Aunis D, Schaeffer E. Functional interactions between C/EBP, Sp1, and COUP-TF regulate human immunodeficiency virus type 1 gene transcription in human brain cells. J Virol 2000, 74:65-73. 10.1128/JVI.74.1.65-73.2000, 111514, 10590092.
186. Hogan TH, Krebs FC, Wigdahl B. Regulation of human immunodeficiency virus type 1 gene expression and pathogenesis by CCAAT/enhancer binding proteins in cells of the monocyte/macrophage lineage. J Neurovirol 2002, 8(Suppl 2):21-26. 10.1080/13550280290167911, 12491147.
187. Krebs FC, Goodenow MM, Wigdahl B. Neuroglial ATF/CREB factors interact with the human immunodeficiency virus type 1 long terminal repeat. J Neurovirol 1997, 3(Suppl 1):S28-32.
188. Rabbi MF, Saifuddin M, Gu DS, Kagnoff MF, Roebuck KA. U5 region of the human immunodeficiency virus type 1 long terminal repeat contains TRE-like cAMP-responsive elements that bind both AP-1 and CREB/ATF proteins. Virology 1997, 233:235-245. 10.1006/viro.1997.8602, 9201233.
189. Roebuck KA, Brenner DA, Kagnoff MF. Identification of c-fos-responsive elements downstream of TAR in the long terminal repeat of human immunodeficiency virus type-1. J Clin Invest 1993, 92:1336-1348. 10.1172/JCI116707, 288275, 8376588.
190. Jia S, Noma K, Grewal SI. RNAi-independent heterochromatin nucleation by the stress-activated ATF/CREB family proteins. Science 2004, 304:1971-1976. 10.1126/science.1099035, 15218150.
191. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004, 117:5965-5973. 10.1242/jcs.01589, 15564374.
192. Chen P, Flory E, Avots A, Jordan BW, Kirchhoff F, Ludwig S, Rapp UR. Transactivation of naturally occurring HIV-1 long terminal repeats by the JNK signaling pathway. The most frequent naturally occurring length polymorphism sequence introduces a novel binding site for AP-1 factors. J Biol Chem 2000, 275:20382-20390. 10.1074/jbc.M001149200, 10764760.
193. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3:859-868. 10.1038/nrc1209, 14668816.
194. Ito T, Yamauchi M, Nishina M, Yamamichi N, Mizutani T, Ui M, Murakami M, Iba H. Identification of SWI.SNF complex subunit BAF60a as a determinant of the transactivation potential of Fos/Jun dimers. J Biol Chem 2001, 276:2852-2857. 10.1074/jbc.M009633200, 11053448.
195. Herschman HR. Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 1991, 60:281-319. 10.1146/annurev.bi.60.070191.001433, 1883198.
196. Datta R, Sherman ML, Stone RM, Kufe D. Expression of the jun-B gene during induction of monocytic differentiation. Cell Growth Differ 1991, 2:43-49.
197. Sherman ML, Stone RM, Datta R, Bernstein SH, Kufe DW. Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem 1990, 265:3320-3323.
198. Lord KA, Abdollahi A, Hoffman-Liebermann B, Liebermann DA. Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation. Mol Cell Biol 1993, 13:841-851. 358967, 8423806.
199. Szabo E, Preis LH, Birrer MJ. Constitutive cJun expression induces partial macrophage differentiation in U-937 cells. Cell Growth Differ 1994, 5:439-446.
200. Li J, King I, Sartorelli AC. Differentiation of WEHI-3B D+ myelomonocytic leukemia cells induced by ectopic expression of the protooncogene c-jun. Cell Growth Differ 1994, 5:743-751.
201. Xanthoudakis S, Miao G, Wang F, Pan YC, Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. Embo J 1992, 11:3323-3335. 556867, 1380454.
202. Monick MM, Carter AB, Hunninghake GW. Human alveolar macrophages are markedly deficient in REF-1 and AP-1 DNA binding activity. J Biol Chem 1999, 274:18075-18080. 10.1074/jbc.274.25.18075, 10364260.
203. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 1997, 94:3633-3638. 10.1073/pnas.94.8.3633, 20492, 9108029.
204. Bossis G, Malnou CE, Farras R, Andermarcher E, Hipskind R, Rodriguez M, Schmidt D, Muller S, Jariel-Encontre I, Piechaczyk M. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol 2005, 25:6964-6979. 10.1128/MCB.25.16.6964-6979.2005, 1190241, 16055710.
205. Garaude J, Farras R, Bossis G, Charni S, Piechaczyk M, Hipskind RA, Villalba M. SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol 2008, 180:5983-5990.
206. Boyle WJ, Smeal T, Defize LH, Angel P, Woodgett JR, Karin M, Hunter T. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 1991, 64:573-584. 10.1016/0092-8674(91)90241-P, 1846781.
207. Friedman AD. C/EBPalpha induces PU.1 and interacts with AP-1 and NF-kappaB to regulate myeloid development. Blood Cells Mol Dis 2007, 39:340-343. 10.1016/j.bcmd.2007.06.010, 2083642, 17669672.
208. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993, 268:14553-14556.
209. Seger R, Krebs EG. The MAPK signaling cascade. Faseb J 1995, 9:726-735.
210. Yang X, Chen Y, Gabuzda D. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB. J Biol Chem 1999, 274:27981-27988. 10.1074/jbc.274.39.27981, 10488148.
211. Leppa S, Saffrich R, Ansorge W, Bohmann D. Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. Embo J 1998, 17:4404-4413. 10.1093/emboj/17.15.4404, 1170773, 9687508.
212. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995, 270:16483-16486.
213. Stein B, Baldwin AS, Ballard DW, Greene WC, Angel P, Herrlich P. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. Embo J 1993, 12:3879-3891. 413671, 8404856.
214. Biggs TE, Cooke SJ, Barton CH, Harris MP, Saksela K, Mann DA. Induction of activator protein 1 (AP-1) in macrophages by human immunodeficiency virus type-1 NEF is a cell-type-specific response that requires both hck and MAPK signaling events. J Mol Biol 1999, 290:21-35. 10.1006/jmbi.1999.2849, 10388555.
215. Berkhout B, Jeang KT. trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis. J Virol 1989, 63:5501-5504. 251225, 2479775.
216. Feng S, Holland EC. HIV-1 tat trans-activation requires the loop sequence within tar. Nature 1988, 334:165-167. 10.1038/334165a0, 3386755.
217. Herrmann CH, Rice AP. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J Virol 1995, 69:1612-1620. 188757, 7853496.
218. Yang X, Gold MO, Tang DN, Lewis DE, Aguilar-Cordova E, Rice AP, Herrmann CH. TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci USA 1997, 94:12331-12336. 10.1073/pnas.94.23.12331, 24930, 9356449.
219. Kao SY, Calman AF, Luciw PA, Peterlin BM. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 1987, 330:489-493. 10.1038/330489a0, 2825027.
220. Laspia MF, Rice AP, Mathews MB. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 1989, 59:283-292. 10.1016/0092-8674(89)90290-0, 2553266.
221. Raha T, Cheng SW, Green MR. HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. PLoS Biol 2005, 3:e44. 10.1371/journal.pbio.0030044, 546330, 15719058.
222. Wang Y, Liu XY, De Clercq E. Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof. Mini Rev Med Chem 2009, 9:379-385. 10.2174/138955709789055207, 19275730.
223. D'Orso I, Frankel AD. Tat acetylation modulates assembly of a viral-host RNA-protein transcription complex. Proc Natl Acad Sci USA 2009, 106:3101-3106. 10.1073/pnas.0900012106, 2651313, 19223581.
224. Molle D, Maiuri P, Boireau S, Bertrand E, Knezevich A, Marcello A, Basyuk E. A real-time view of the TAR:Tat:P-TEFb complex at HIV-1 transcription sites. Retrovirology 2007, 4:36. 10.1186/1742-4690-4-36, 1904240, 17537237.
225. Kimura A, Horikoshi M. Tip60 acetylates six lysines of a specific class in core histones in vitro. Genes Cells 1998, 3:789-800. 10.1046/j.1365-2443.1998.00229.x, 10096020.
226. Ott M, Schnolzer M, Garnica J, Fischle W, Emiliani S, Rackwitz HR, Verdin E. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr Biol 1999, 9:1489-1492. 10.1016/S0960-9822(00)80120-7, 10607594.
227. Vardabasso C, Manganaro L, Lusic M, Marcello A, Giacca M. The histone chaperone protein Nucleosome Assembly Protein-1 (hNAP-1) binds HIV-1 Tat and promotes viral transcription. Retrovirology 2008, 5:8. 10.1186/1742-4690-5-8, 2266780, 18226242.
228. Marzio G, Tyagi M, Gutierrez MI, Giacca M. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci USA 1998, 95:13519-13524. 10.1073/pnas.95.23.13519, 24851, 9811832.
229. Deng L, de la Fuente C, Fu P, Wang L, Donnelly R, Wade JD, Lambert P, Li H, Lee CG, Kashanchi F. Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 2000, 277:278-295. 10.1006/viro.2000.0593, 11080476.
230. Benkirane M, Chun RF, Xiao H, Ogryzko VV, Howard BH, Nakatani Y, Jeang KT. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J Biol Chem 1998, 273:24898-24905. 10.1074/jbc.273.38.24898, 9733796.
231. Treand C, du Chene I, Bres V, Kiernan R, Benarous R, Benkirane M, Emiliani S. Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. Embo J 2006, 25:1690-1699. 10.1038/sj.emboj.7601074, 1440843, 16601680.
232. Harrich D, Garcia J, Wu F, Mitsuyasu R, Gonazalez J, Gaynor R. Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat. J Virol 1989, 63:2585-2591. 250732, 2657100.
233. Berkhout B, Jeang KT. Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat. J Virol 1992, 66:139-149. 238269, 1727476.
234. Jeang KT, Chun R, Lin NH, Gatignol A, Glabe CG, Fan H. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol 1993, 67:6224-6233. 238044, 7690421.
235. Loregian A, Bortolozzo K, Boso S, Caputo A, Palu G. Interaction of Sp1 transcription factor with HIV-1 Tat protein: looking for cellular partners. FEBS Lett 2003, 543:61-65. 10.1016/S0014-5793(03)00399-5, 12753906.
236. Loregian A, Bortolozzo K, Boso S, Sapino B, Betti M, Biasolo MA, Caputo A, Palu G. The Sp1 transcription factor does not directly interact with the HIV-1 Tat protein. J Cell Physiol 2003, 196:251-257. 10.1002/jcp.10271, 12811817.
237. Hidalgo-Estevez AM, Gonzalez E, Punzon C, Fresno M. Human immunodeficiency virus type 1 Tat increases cooperation between AP-1 and NFAT transcription factors in T cells. J Gen Virol 2006, 87:1603-1612. 10.1099/vir.0.81637-0, 16690925.
238. Biswas DK, Salas TR, Wang F, Ahlers CM, Dezube BJ, Pardee AB. A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter. J Virol 1995, 69:7437-7444. 189681, 7494249.
239. Demarchi F, Gutierrez MI, Giacca M. Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J Virol 1999, 73:7080-7086. 112801, 10400814.
240. Kumar A, Manna SK, Dhawan S, Aggarwal BB. HIV-Tat protein activates c-Jun N-terminal kinase and activator protein-1. J Immunol 1998, 161:776-781.
241. Subbramanian RA, Kessous-Elbaz A, Lodge R, Forget J, Yao XJ, Bergeron D, Cohen EA. Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med 1998, 187:1103-1111. 10.1084/jem.187.7.1103, 2212198, 9529326.
242. Cohen EA, Terwilliger EF, Jalinoos Y, Proulx J, Sodroski JG, Haseltine WA. Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr 1990, 3:11-18.
243. Philippon V, Matsuda Z, Essex M. Transactivation is a conserved function among primate lentivirus Vpr proteins but is not shared by Vpx. J Hum Virol 1999, 2:167-174.
244. Sawaya BE, Khalili K, Gordon J, Taube R, Amini S. Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem 2000, 275:35209-35214. 10.1074/jbc.M005197200, 10931842.
245. Vanitharani R, Mahalingam S, Rafaeli Y, Singh SP, Srinivasan A, Weiner DB, Ayyavoo V. HIV-1 Vpr transactivates LTR-directed expression through sequences present within -278 to -176 and increases virus replication in vitro. Virology 2001, 289:334-342. 10.1006/viro.2001.1153, 11689055.
246. Zhao LJ, Mukherjee S, Narayan O. Biochemical mechanism of HIV-I Vpr function. Specific interaction with a cellular protein. J Biol Chem 1994, 269:15577-15582.
247. Yu XF, Matsuda M, Essex M, Lee TH. Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein. J Virol 1990, 64:5688-5693. 248631, 2145446.
248. Cohen EA, Dehni G, Sodroski JG, Haseltine WA. Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol 1990, 64:3097-3099. 249501, 2139896.
249. Caly L, Saksena NK, Piller SC, Jans DA. Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor. Retrovirology 2008, 5:67. 10.1186/1742-4690-5-67, 2515335, 18638397.
250. Emerman M. HIV-1, Vpr and the cell cycle. Curr Biol 1996, 6:1096-1103. 10.1016/S0960-9822(02)00676-0, 8805364.
251. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, Srinivasan A, Collman R. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 1994, 200:623-631. 10.1006/viro.1994.1225, 8178448.
252. Balotta C, Lusso P, Crowley R, Gallo RC, Franchini G. Antisense phosphorothioate oligodeoxynucleotides targeted to the vpr gene inhibit human immunodeficiency virus type 1 replication in primary human macrophages. J Virol 1993, 67:4409-4414. 237816, 8510229.
253. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206:935-944. 10.1006/viro.1995.1016, 7531918.
254. Levy DN, Refaeli Y, Weiner DB. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol 1995, 69:1243-1252. 188697, 7815499.
255. Hattori N, Michaels F, Fargnoli K, Marcon L, Gallo RC, Franchini G. The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages. Proc Natl Acad Sci USA 1990, 87:8080-8084. 10.1073/pnas.87.20.8080, 54896, 2236020.
256. Westervelt P, Henkel T, Trowbridge DB, Orenstein J, Heuser J, Gendelman HE, Ratner L. Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol 1992, 66:3925-3931. 241183, 1533883.
257. Chen R, Le Rouzic E, Kearney JA, Mansky LM, Benichou S. Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. J Biol Chem 2004, 279:28419-28425. 10.1074/jbc.M403875200, 15096517.
258. Fouchier RA, Meyer BE, Simon JH, Fischer U, Albright AV, Gonzalez-Scarano F, Malim MH. Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol 1998, 72:6004-6013. 110405, 9621063.
259. Popov S, Rexach M, Ratner L, Blobel G, Bukrinsky M. Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem 1998, 273:13347-13352. 10.1074/jbc.273.21.13347, 9582382.
260. Popov S, Rexach M, Zybarth G, Reiling N, Lee MA, Ratner L, Lane CM, Moore MS, Blobel G, Bukrinsky M. Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J 1998, 17:909-917. 10.1093/emboj/17.4.909, 1170440, 9463369.
261. Vodicka MA, Koepp DM, Silver PA, Emerman M. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 1998, 12:175-185. 10.1101/gad.12.2.175, 316441, 9436978.
262. Le Rouzic E, Mousnier A, Rustum C, Stutz F, Hallberg E, Dargemont C, Benichou S. Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1. J Biol Chem 2002, 277:45091-45098. 10.1074/jbc.M207439200, 12228227.
263. Jacquot G, Le Rouzic E, David A, Mazzolini J, Bouchet J, Bouaziz S, Niedergang F, Pancino G, Benichou S. Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. Retrovirology 2007, 4:84. 10.1186/1742-4690-4-84, 2211753, 18039376.
264. Levy DN, Refaeli Y, MacGregor RR, Weiner DB. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994, 91:10873-10877. 10.1073/pnas.91.23.10873, 45128, 7971975.
265. Henklein P, Bruns K, Sherman MP, Tessmer U, Licha K, Kopp J, de Noronha CM, Greene WC, Wray V, Schubert U. Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest. J Biol Chem 2000, 275:32016-32026. 10.1074/jbc.M004044200, 10903315.
266. Sherman MP, Schubert U, Williams SA, de Noronha CM, Kreisberg JF, Henklein P, Greene WC. HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology 2002, 302:95-105. 10.1006/viro.2002.1576, 12429519.
267. Varin A, Decrion AZ, Sabbah E, Quivy V, Sire J, Van Lint C, Roques BP, Aggarwal BB, Herbein G. Synthetic Vpr protein activates activator protein-1, c-Jun N-terminal kinase, and NF-kappaB and stimulates HIV-1 transcription in promonocytic cells and primary macrophages. J Biol Chem 2005, 280:42557-42567. 10.1074/jbc.M502211200, 16243842.
268. Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 1995, 270:25564-25569. 10.1074/jbc.270.43.25564, 7592727.
269. Agostini I, Navarro JM, Bouhamdan M, Willetts K, Rey F, Spire B, Vigne R, Pomerantz R, Sire J. The HIV-1 Vpr co-activator induces a conformational change in TFIIB. FEBS Lett 1999, 450:235-239. 10.1016/S0014-5793(99)00501-3, 10359081.
270. Agostini I, Navarro JM, Rey F, Bouhamdan M, Spire B, Vigne R, Sire J. The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB. J Mol Biol 1996, 261:599-606. 10.1006/jmbi.1996.0485, 8800208.
271. Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, Williams WV, Green DR, Weiner DB. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med 1997, 3:1117-1123. 10.1038/nm1097-1117, 9334723.
272. Roux P, Alfieri C, Hrimech M, Cohen EA, Tanner JE. Activation of transcription factors NF-kappaB and NF-IL-6 by human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8 expression. J Virol 2000, 74:4658-4665. 10.1128/JVI.74.10.4658-4665.2000, 111986, 10775602.
273. Forget J, Yao XJ, Mercier J, Cohen EA. Human immunodeficiency virus type 1 vpr protein transactivation function: mechanism and identification of domains involved. J Mol Biol 1998, 284:915-923. 10.1006/jmbi.1998.2206, 9837715.
274. Hrimech M, Yao XJ, Bachand F, Rougeau N, Cohen EA. Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J Virol 1999, 73:4101-4109. 104189, 10196306.
275. Bednarik DP, Mosca JD, Raj NB. Methylation as a modulator of expression of human immunodeficiency virus. J Virol 1987, 61:1253-1257. 254089, 3469417.
276. Gutekunst KA, Kashanchi F, Brady JN, Bednarik DP. Transcription of the HIV-1 LTR is regulated by the density of DNA CpG methylation. J Acquir Immune Defic Syndr 1993, 6:541-549.
277. Schulze-Forster K, Gotz F, Wagner H, Kroger H, Simon D. Transcription of HIV1 is inhibited by DNA methylation. Biochem Biophys Res Commun 1990, 168:141-147. 10.1016/0006-291X(90)91685-L, 2327994.
278. Bednarik DP, Cook JA, Pitha PM. Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. EMBO J 1990, 9:1157-1164. 551791, 2323336.
279. Marcello A. Latency: the hidden HIV-1 challenge. Retrovirology 2006, 3:7. 10.1186/1742-4690-3-7, 1379657, 16412247.
280. Singh MK, Pauza CD. Extrachromosomal human immunodeficiency virus type 1 sequences are methylated in latently infected U937 cells. Virology 1992, 188:451-458. 10.1016/0042-6822(92)90498-E, 1585628.
281. Ishida T, Hamano A, Koiwa T, Watanabe T. 5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology 2006, 3:69. 10.1186/1742-4690-3-69, 1617119, 17034647.
282. Joel P, Shao W, Pratt K. A nuclear protein with enhanced binding to methylated Sp1 sites in the AIDS virus promoter. Nucleic Acids Res 1993, 21:5786-5793. 10.1093/nar/21.24.5786, 310550, 8284230.
283. Shao W. Characterization of HMBP-2, a DNA-Binding Protein That Binds to HIV-1 LTR When only One of the Three Sp1 Sites Is Methylated. J Biomed Sci 1997, 4:39-46. 10.1007/BF02255592, 11725132.
284. Pion M, Jordan A, Biancotto A, Dequiedt F, Gondois-Rey F, Rondeau S, Vigne R, Hejnar J, Verdin E, Hirsch I. Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol 2003, 77:4025-4032. 10.1128/JVI.77.7.4025-4032.2003, 150653, 12634362.
285. Ciardi M, Sharief MK, Thompson EJ, Salotti A, Vullo V, Sorice F, Cirelli A. High cerebrospinal fluid and serum levels of tumor necrosis factor-alpha in asymptomatic HIV-1 seropositive individuals. Correlation with interleukin-2 and soluble IL-2 receptor. J Neurol Sci 1994, 125:175-179. 10.1016/0022-510X(94)90031-0, 7807163.
286. Ownby RL, Kumar AM, Benny Fernandez J, Moleon-Borodowsky I, Gonzalez L, Eisdorfer S, Waldrop-Valverde D, Kumar M. Tumor Necrosis Factor-alpha Levels in HIV-1 Seropositive Injecting Drug Users. J Neuroimmune Pharmacol 2009,
287. Esser R, Glienke W, von Briesen H, Rubsamen-Waigmann H, Andreesen R. Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus. Blood 1996, 88:3474-3481.
288. Hungness ES, Luo GJ, Pritts TA, Sun X, Robb BW, Hershko D, Hasselgren PO. Transcription factors C/EBP-beta and -delta regulate IL-6 production in IL-1beta-stimulated human enterocytes. J Cell Physiol 2002, 192:64-70. 10.1002/jcp.10116, 12115737.
289. Yang Z, Wara-Aswapati N, Chen C, Tsukada J, Auron PE. NF-IL6 (C/EBPbeta) vigorously activates il1b gene expression via a Spi-1 (PU.1) protein-protein tether. J Biol Chem 2000, 275:21272-21277. 10.1074/jbc.M000145200, 10801783.
290. Pope R, Mungre S, Liu H, Thimmapaya B. Regulation of TNF-alpha expression in normal macrophages: the role of C/EBPbeta. Cytokine 2000, 12:1171-1181. 10.1006/cyto.2000.0691, 10930293.
291. Pope RM, Leutz A, Ness SA. C/EBP beta regulation of the tumor necrosis factor alpha gene. J Clin Invest 1994, 94:1449-1455. 10.1172/JCI117482, 295278, 7929820.
292. Swingler S, Mann A, Jacque J, Brichacek B, Sasseville VG, Williams K, Lackner AA, Janoff EN, Wang R, Fisher D, Stevenson M. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999, 5:997-103. 10.1038/12433, 10470075.
293. Zylla D, Li Y, Bergenstal E, Merrill JD, Douglas SD, Mooney K, Guo CJ, Song L, Ho WZ. CCR5 expression and beta-chemokine production during placental neonatal monocyte differentiation. Pediatr Res 2003, 53:853-858. 10.1203/01.PDR.0000059749.82140.4A, 12621126.
294. Naif HM, Li S, Alali M, Sloane A, Wu L, Kelly M, Lynch G, Lloyd A, Cunningham AL. CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol 1998, 72:830-836. 109444, 9420295.
295. Arfi V, Riviere L, Jarrosson-Wuilleme L, Goujon C, Rigal D, Darlix JL, Cimarelli A. Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1. J Virol 2008, 82:6557-6565. 10.1128/JVI.02321-07, 2447095, 18417568.
296. Triques K, Stevenson M. Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J Virol 2004, 78:5523-5527. 10.1128/JVI.78.10.5523-5527.2004, 400363, 15113933.
297. Demarchi F, D'Agaro P, Falaschi A, Giacca M. In vivo footprinting analysis of constitutive and inducible protein-DNA interactions at the long terminal repeat of human immunodeficiency virus type 1. J Virol 1993, 67:7450-7460. 238211, 8230466.
298. Siddappa NB, Venkatramanan M, Venkatesh P, Janki MV, Jayasuryan N, Desai A, Ravi V, Ranga U. Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein. Retrovirology 2006, 3:53. 10.1186/1742-4690-3-53, 1564039, 16916472.
299. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des 2005, 11:2873-2887. 10.2174/1381612054546699, 16101443.
300. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002, 62:6659-6666.
301. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000, 97:4227-4232. 10.1073/pnas.97.8.4227, 18206, 10760290.
302. Jing N, Zhu Q, Yuan P, Li Y, Mao L, Tweardy DJ. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther 2006, 5:279-286. 10.1158/1535-7163.MCT-05-0302, 16505101.
303. Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 2004, 64:6603-6609. 10.1158/0008-5472.CAN-03-4041, 15374974.
304. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 2003, 9:2510-2519.
305. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009, 8:33-40. 10.1038/nrd2781, 2729321, 19116625.
306. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. 10.1038/nature04870, 16724054.
307. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 2004, 10:3333-3341. 10.1158/1078-0432.CCR-03-0366, 15161687.
308. Huang YT, Pan SL, Guh JH, Chang YL, Lee FY, Kuo SC, Teng CM. YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther 2005, 4:1628-1635. 10.1158/1535-7163.MCT-05-0090, 16227413.
309. Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 2005, 11:1287-1293.
310. Schon M, Wienrich BG, Kneitz S, Sennefelder H, Amschler K, Vohringer V, Weber O, Stiewe T, Ziegelbauer K, Schon MP. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst 2008, 100:862-875. 10.1093/jnci/djn174, 18544741.
311. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008, 123:951-957. 10.1002/ijc.23593, 18521906.
312. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3:17-26. 10.1038/nrd1279, 14708018.
313. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001, 20:4519-4527. 10.1038/sj.onc.1204623, 11494147.
314. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
315. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101:2377-2380. 10.1182/blood-2002-06-1768, 12424198.
316. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S. Tolfenamic Acid Inhibits Esophageal Cancer Through Repression of Specificity Proteins and c-Met. Carcinogenesis 2009,
317. Abdelrahim M, Smith R, Burghardt R, Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 2004, 64:6740-6749. 10.1158/0008-5472.CAN-04-0713, 15374992.
318. Abdelrahim M, Baker CH, Abbruzzese JL, Sheikh-Hamad D, Liu S, Cho SD, Yoon K, Safe S. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007, 67:3286-3294. 10.1158/0008-5472.CAN-06-3831, 17409437.
319. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006, 98:855-868.
320. Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther. 2009,
321. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000, 18:371-375.
322. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001, 19:1985-1992.
323. Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:1740-1745. 10.1200/jco.2003.09.057, 12735303.
324. Kim JC, Saha D, Cao Q, Choy H. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol 2004, 71:213-221. 10.1016/j.radonc.2004.03.006, 15110456.
325. Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, Kaufmann SH, Atherton PJ, Sloan JA, Daiss MK, Adjei AA, Erlichman C. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005, 11:5935-5941. 10.1158/1078-0432.CCR-04-2566, 16115936.
326. Biglione S, Byers SA, Price JP, Nguyen VT, Bensaude O, Price DH, Maury W. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 2007, 4:47. 10.1186/1742-4690-4-47, 1948018, 17625008.
327. Suzuki T, Yamamoto N, Nonaka M, Hashimoto Y, Matsuda G, Takeshima SN, Matsuyama M, Igarashi T, Miura T, Tanaka R, Kato S, Aida Y. Inhibition of human immunodeficiency virus type 1 (HIV-1) nuclear import via Vpr-Importin alpha interactions as a novel HIV-1 therapy. Biochem Biophys Res Commun 2009, 380:838-843. 10.1016/j.bbrc.2009.01.180, 19338763.
328. Watanabe N, Nishihara Y, Yamaguchi T, Koito A, Miyoshi H, Kakeya H, Osada H. Fumagillin suppresses HIV-1 infection of macrophages through the inhibition of Vpr activity. FEBS Lett 2006, 580:2598-2602. 10.1016/j.febslet.2006.04.007, 16631749.
329. Van Duyne R, Cardenas J, Easley R, Wu W, Kehn-Hall K, Klase Z, Mendez S, Zeng C, Chen H, Saifuddin M, Kashanchi F. Effect of transcription peptide inhibitors on HIV-1 replication. Virology 2008, 376:308-322. 10.1016/j.virol.2008.02.036, 18455747.
330. Iguchi T, Ishikawa H, Matumoto H, Mizuno M, Goto K, Hamasaki K. Amino disaccharides having an alpha-(1-->4) or a beta-(1-->4) linkage, their synthesis and evaluation as a potential inhibitor for HIV-1 TAR-Tat. Nucleic Acids Symp Ser (Oxf) 2005, 169-170. 10.1093/nass/49.1.169, 17150687.
331. Lapidot A, Berchanski A, Borkow G. Insight into the mechanisms of aminoglycoside derivatives interaction with HIV-1 entry steps and viral gene transcription. FEBS J 2008, 275:5236-5257. 10.1111/j.1742-4658.2008.06657.x, 18803669.
332. Riguet E, Desire J, Boden O, Ludwig V, Gobel M, Bailly C, Decout JL. Neamine dimers targeting the HIV-1 TAR RNA. Bioorg Med Chem Lett 2005, 15:4651-4655. 10.1016/j.bmcl.2005.07.082, 16153833.
333. Hwang S, Tamilarasu N, Kibler K, Cao H, Ali A, Ping YH, Jeang KT, Rana TM. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J Biol Chem 2003, 278:39092-39103. 10.1074/jbc.M301749200, 12857725.